ClinicalTrials.gg
Active, not recruitingNCT04684706ciTBSUpdated Jan 16, 2026

Compressed Intermittent Theta Burst Stimulation

An interventional study of intermittent Theta Burst Stimulation in Treatment Resistant Depression, sponsored by University of Pennsylvania. Active, not recruiting at 2 sites in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-01-16.

Sponsored by University of Pennsylvania · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Registered 7 months after the study started (first participant enrolled Feb 2020, registered Oct 2020).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 205 studies in Depressive Disorder, Treatment-Resistant with a site in United States — 43 open to participants now, 65 under way, 6 of them phase 3. Depressive Disorder, Treatment-Resistant · United States.

Planned enrollment
88th of 181
40 · median 38
Started
2020
with 14 others
No phase
72 of 205
21 open now
Primary completion
2026-11
later than 15 of 64 live
Registered
114th of 205
by date

Among the 205 studies in Depressive Disorder, Treatment-Resistant with a site in United States, this one is the 88th largest by planned enrollment of the 181 interventional ones that give a count, is one of 15 that started in 2020, is one of 72 with no phase, reaches primary completion later than 15 of the 64 other live ones, and was the 114th registered.

Depressive Disorder, Treatment-Resistant

450 studies on the registry are indexed under Depressive Disorder, Treatment-Resistant; 148 are open to participants now.

Browse Depressive Disorder, Treatment-Resistant studies →

Open to participants now

43 of the 205 studies in Depressive Disorder, Treatment-Resistant with a site in United States are open now. Recruiting first, the newest first:

38 more — sign in →

All 43 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 115 Depressive Disorder, Treatment-Resistant studies recruiting now, 27 (23%) set no upper age limit and 76 (66%) stop at 75 or younger; 1 takes children under 18; 13 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 205 studies in Depressive Disorder, Treatment-Resistant with a site in United States, or all of them as a file.
02

Study summary

In this proposal the investigators will use an accelerated TMS protocol that concentrates the magnetic stimulation that would usually occur over 6 weeks into 10 treatment sessions per days, for 5 consecutive days in patient with treatment-refractory depression. This protocol will build on a previously published study demonstrating clinical efficacy of intermittent theta-burst stimulation (iTBS) on left dorsolateral prefrontal cortex (L-dlPFC) in a treatment refractory population.

Read the detailed description

Major depressive disorder (MDD) is a disabling mental disorder with a lifetime prevalence of up to16% . Approximately 30% of MDD patients suffer treatment resistant depression (TRD), with at least 2 failed adequate trials of pharmacotherapy. Repetitive transcranial magnetic stimulation (rTMS) has been shown to be a safe treatment for TRD, yet the standard clinical technique for using it as treatment depressive disorders is associated with limited efficacy to date. Among the potential causes of limited efficacy have been the scalp based targeting technique that is currently the most common targeting method rather than techniques that incorporate functional magnetic resonance imaging (fMRI) neuronavigation, which have been shown to have greater efficacy. Image guided TMS can target specific functional brain networks with greater resolution that takes into account individual differences in brain anatomy.

Another technique for improving treatment efficacy, shown to modulate cortical excitability, may be the application of intermittent theta-burst stimulation in regular intervals, which has been shown to be no different than a longer-in-time application of rTMS. Paired with the evidence that iTBS has produced significant antidepressant responses in severely depressed individuals, and that relapse in depressive states predicts diminished efficacy of treatment as well as increased quantity of TBS pulses to have a beneficial effect, these recent iTBS findings suggest that iTBS may offer a valid treatment alternative to options that have proven otherwise ineffective in treating TRD. Therefore, the investigators aim to administer iTBS to severely-depressed participant in a shorter amount of time, in order to improve their antidepressant outcome.

Significance: This protocol builds on different notions:

  1. iTBS is not different in treatment outcome than rTMS while applying the same amount of pulses in shorter amount of time;
  2. The degree of treatment resistance is indicative of iTBS quantity needed to obtain an antidepressant treatment
  3. Repeated iTBS produces a significant effect in treating refractory depression
  4. Decreasing the interval between iTBS applications enhanced positive treatment outcomes.

Therefore, the compression of iTBS pulses with shorter intervals between sessions is hypothesized to have an increased beneficial effect on individuals affected by treatment-resistant depression.

03

Conditions studied

  • Treatment Resistant Depression

Keywords

  • TMS
  • fMRI
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Gender, inclusive
  • 18 - 70 years of age
  • Meets criteria for primary diagnosis of MDD
  • Patients must be fluent in English
  • Participants must have the ability to provide consent
  • Montgomery Asberg Depression Rating Scale score ≥20
  • Failed 2+ prior treatments (treatment-)
  • May be on current anti-depressant medication at the discretion of PI, if not exceeding doses that would make TMS an increased risk

Exclusion criteria

Exclusion Criteria:

  • Pregnancy (Female participants)
  • MRI
  • Medical condition that interferes with the collection or interpretation of MRI data
  • Implanted devices such as: aneurysm clip or cardiac pacemaker
  • Diagnosis of stroke, epilepsy, or other neurological disorders interfering with treatment at PI discretion
  • Any factor the investigator believe may affect participant safety or compliance (ex: ≥100 miles from clinic)
  • Current alcohol or substance use disorder in last 3 months
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Other
    Compressed iTBS schedule

    Stimulation 3-pulse 50-Hz bursts at 5-Hz for 2-s trains, with trains every 10 s, for 10 minutes, 10 times a day, for 5 consecutive days.

    Device: intermittent Theta Burst Stimulation

Interventions

  • Deviceintermittent Theta Burst Stimulation

    The present study will utilize TMS dosage of iTBS of 18 000 pulses a day for 5 consecutive days.

06

What researchers measure

Primary outcomes

  1. Depressive Symptoms Change

    Depressive symptoms will be measured before and after treatment by means of the clinician-administered Montgomery Asberg Depression Rating Scale (MADRS) (0-60, lower scores indicate lower depressive symptoms) and the self report Beck Depression Inventory (BDI II) (0-30, lower scores indicate lower depressive symptoms). Change will be measured by comparing measurements pre- and post- on the same measures. The bigger the change, the bigger the reduction in depressive symptoms.

    Time frame: 2 Weeks

Secondary outcomes

  1. Self report Symptom Change

    Depressive symptoms will be measured before and after treatment by means of the self report Beck Depression Inventory (BDI II) (0-30, lower scores indicate lower depressive symptoms). Change will be measured by comparing measurements pre- and post- on the same measures. The bigger the change, the bigger the reduction in depressive symptoms.

    Time frame: 2 weeks

07

Study locations

2 sites
  • Department of Interventional Psychiatry, University of California San Diego
    La Jolla, California 92093, United States
  • Center for Neuromodulation in Depression and Stress
    Philadelphia, Pennsylvania 19104, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2020 (actual). Primary completion is estimated for Nov 2026, 81 months after the start.

Of 136 non-industry interventional studies with no phase under Depressive Disorder, Treatment-Resistant, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 88. This study's planned 81 months is above that.

Counting every sponsor, half of 140 studies reached it within 50 months; a quarter within 22 and three quarters within 88.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 12, 2020
First posted
Dec 24, 2020
StartActual
Feb 20, 2020
Primary completionEst.
Nov 30, 2026
CompletionEst.
Jan 20, 2027
Last update
Jan 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04684706
Responsible party
Yvette Sheline (Director, Center for Neuromodulation in Depression and Stress (CNDS), University of Pennsylvania) — Principal investigator
First posted
Dec 24, 2020
Start date
Feb 20, 2020
Primary completion
Nov 30, 2026 (estimated)
Completion
Jan 20, 2027 (estimated)
Last update
Jan 16, 2026

Study contacts

Yvette Sheline, MD
principal investigator · University of Pennsylvania

Oversight

FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion